Pharvaris N.V. (PHVS)

Signal: A scenario-weighted DCF with a 75% probability on the on-demand indication and 40% on prophylactic yields a risk-adjusted value of $32, and at $34.91 the stock is already pricing in roughly 70% odds of on-demand success — the math says you're paying for optimism, not getting a margin of safety. Conviction: Conviction is held back by a single contested dependency: the prophylactic readout in Q3 2026 is a true binary — if CHAPTER-3 fails, the bear case of $18 is a real possibility, and the base case offers no cushion at current prices.

Signal: The enterprise value of ~$2.1 billion represents a $1.8 billion bet on a single unapproved molecule with zero revenue, and the stock trades at 8.2x tangible book with three binary events still ahead — any one of which can destroy the thesis. Conviction: Conviction is reinforced by the clean 20-F (no accounting red flags) and the pattern of universal analyst euphoria — 12 of 13 Strong Buys — which historically signals that the easy money has already been made.

Signal: The company has zero revenue and zero earnings, so the core PEG framework breaks down entirely, yet a pristine balance sheet with zero debt and $284 million in cash provides a survival runway that few pre-revenue biotechs enjoy. Conviction: Conviction is held back by the inability to apply any earnings-based framework — this is a binary catalyst bet, not a business with observable fundamentals, and the thin-volume zone above $30.80 raises the specter of a fast, violent move in either direction.

Signal: The convergence of a validated B2 antagonist mechanism with the first oral delivery platform in HAE — a single molecule serving both on-demand and prophylaxis — could expand the treated patient pool by 30–50% and create a franchise capable of $1B+ in peak sales across a $6–8B addressable market. Conviction: Conviction is held back by the stock already pricing in much of the optimism; the expected probability-weighted return is positive but depends almost entirely on the CHAPTER-3 prophylaxis readout — a binary outcome with a 30% bear-case probability of collapsing to ~$10.

Signal: There is no economic moat, no earnings, no product, and no customer base — the entire value rests on one molecule in a market where Takeda and CSL Behring already own entrenched injectable franchises with proven billion-dollar revenue streams. Conviction: Conviction is near-absolute because the framework requires durable competitive advantage, consistent high ROE, and predictable free cash flow — and PHVS offers none of these; the $168M annual cash burn funded by dilutive equity raises is the opposite of compounding wealth.

Signal: An enterprise value of $2.1 billion capitalizes the pipeline at roughly $1.8 billion for a company with negative ROE, no revenue, and a peak-sales ceiling that — even under optimistic assumptions — would imply paying 4–5x peak sales for a drug that hasn't been approved yet, in a business the analyst himself puts in the 'too hard' pile. Conviction: Conviction is low because the entire framework rests on a single mental model — inversion — which shows asymmetric downside: any of the three binary events ahead could produce a 50–90% drawdown, and the upside even if everything works is only 2–3x.